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Hypertension in Autosomal Dominant Polycystic Kidney
Disease: A Clinical and Basic Science Perspective
Shobha Ratnam and Surya M. Nauli
Department of Pharmacology and Medicine, University of Toledo, Toledo, Ohio, USA

Abstract
Background and Aims: Cardiovascular complications are major causes of morbidity and mortality in
patients with autosomal dominant polycystic kidney disease (ADPKD). In particular, hypertension
is insidious and remains a continuous problem that evolves during the course of the disease. Hypertension in ADPKD has been associated with abnormality in the renin-angiotensin-aldosterone
system (RAAS). Early vascular changes have also been reported in young ADPKD patients. In
addition, the cellular functions of mechanosensory cilia within vascular system have emerged
recently. The basic and clinical perspectives of RAAS, vascular remodeling and sensory cilia are
reviewed with regard to hypertension in ADPKD.
Keywords: Angiotensin, Blood Pressure, Cardiovascular, Cilia Biology, Hypertension, ADPKD

Introduction
Autosomal dominant polycystic kidney disease
(ADPKD) is a systemic hereditary disorder that affects more than 12.5 million individuals worldwide.
Thus, ADPKD is the most common life-threatening
hereditary genetic disease, compared to the numbers
of individuals affected by cystic fibrosis, Downs
syndrome, hemophilia, muscular dystrophy, and
sickle cell anemia, combined (1, 2). Approximately
600,000 Americans have the disease, and the prevalence of the disease varies between 1:400 and 1:
1000 in the general population (3, 4).
ADPKD is characterized by a long course of
normal glomerular filtration rate (GFR), microalbuminuria and early development of hypertension, followed by a persistent decrease in GFR in
the fifth to sixth decades. This eventually leads to
end stage renal disease in approximately 50% of
patients (5, 6). Although the kidneys are the major
sites of clinical disease (Figure 1), the prevalence of

extrarenal manifestations in ADPKD is high. These
extrarenal manifestations include cyst formation
in other ductal organs and various cardiovascular
abnormalities (7-11). Cardiovascular abnormalities
may include hypertension, cerebral and coronary
artery aneurysms, mitral valve prolapse, aortic root
dilation, dissection of the thoracic aorta, aneurysm
formation in the abdominal aorta, vascular ectasia,
and abnormal function of the microvascular bed
(12-15).
The frequencies of extrarenal manifestations of
ADPKD include hypertension (78%), hepatic cysts
(75%), diverticulosis (70%), ovarian cysts (40%),
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Figure 1. Autosomal dominant polycystic kidney
a. Polycystic kidney is characterized by the presence of
numerous fluid-filled cysts. An ADPKD kidney can reach
over 10 inches in length, about 3-4 times larger than a normal
four-inch long kidney. b. Fluid accumulation in the cysts
contributes to the weight and size of an ADPKD kidney. c. In
contrast to heavier tissue mass in renal carcinoma, an ADPKD
kidney could lose about 7-28 ounces of weight after fluid cyst
removal. This is an important phenotypic characteristic that
despite its large size and volume, an ADPKD kidney actually
contains equal or less tissue mass than a normal kidney.
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cardiac valve disorders (25%), inguinal hernias (15%)
and intracranial aneurysms (10%) (16). Prevalence
of intracranial aneurysms in ADPKD individuals
is increased several folds compared to the general
population (4.0-11.7% versus 1.0%) and intracranial
aneurysm rupture remains a devastating complication in ADPKD (17). Screening ADPKD individuals
with a family history of sub-arachnoid hemorrhage
is thus essential, because intracranial aneurysms appears to cluster in ADPKD families with history of
cerebral hemorrhage (18). A retrospective study of
77 ADPKD individuals with aneurysms showed that
only 29% were normotensive within one year prior
to rupture (19). In particular, renal function was normal in half of these patients. Therefore, hypertension
is an associated finding in these individuals. More
important, hypertension has been a continual risk
factor for cardiovascular diseases in ADPKD (15).
It occurs early in ADPKD individuals, compared
to their age-matched cohorts and remains the most
frequent cause of mortality (12).
The discovery of the PKD1 and PKD2 genes has
opened up avenues of research in molecular biology
to further understand the role of genetic mutations
in the pathogenesis of this devastating disease.
PKD1 encodes for polycystin-1, which is involved
in the mechanosensory function, and polycystin-2
encoded by PKD2 is a sensory calcium channel (2029). The PKD1 mutation affects nearly 85% of the
patients with ADPKD, and they have a shorter and
more severe disease progressions than patients with
PKD2 mutation; i.e. 54 years compared to 74 years,
respectively (30).
While numerous progresses have been reported
about the pathology and pathogenesis of cystic
kidneys (31), this article is intended to review the
hypertension aspect of ADPKD. In particular, several ideas of “cilia hypothesis” have been discussed
regarding polycystic kidneys (32-36). These ideas
will be revisited to understand the constituents of the
cardiovascular complications, such as hypertension,
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with respect to the new clinical and basic science
development in ADPKD.
Pathogenesis of hypertension in ADPKD
Progressive enlargement of cysts by magnetic
resonance imaging, as studied in the recent CRISP
(The consortium for radiologic imaging studies of
polycystic kidney disease) trial and other studies,
has been linked to deterioration of renal function
in ADPKD (6, 37, 38). These studies have shown
that renal function remains relatively stable until the
renal volume reaches 1500 cm3, at which point there
is a rapid decline that necessitates renal replacement
therapy (39). It is believed that distortion of the renal
architecture leads to structural damage and tubular
dysfunction and results in activation of the reninangiotensin-aldosterone system (RAAS). These
findings have also been reported in hypertensive
animal models of polycystic kidney disease (40,
41). This mechanism, which is well documented
in the clinical course of this disease (42), has also
been proposed to contribute to the increased blood
pressure seen early in ADPKD patients. Changes
in the vasculatures during the course of the disease
progression have also been observed in both human
(43-47) and animal (48-52) studies. Most recently,
ciliary defects have also been proposed to cause the
complication of hypertension in ADPKD (20, 25).
We will therefore look at these possibilities as the
origins of hypertension in ADPKD.
Renin-angiotensin system
Compared with age-matched healthy control subjects, an increase in intrarenal RAAS activity is seen
in ADPKD patients, regardless of their blood pressure
and renal function (53). Angiotensin II has been implicated in the development of vascular hypertrophy,
resulting in structural remodeling (54). Angiotensin
II generation via ACE-independent chymase-like
pathways has been shown in ADPKD kidneys,
making it an attractive target for pharmacological
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intervention (Figure 2). Control of blood pressure in
most renal diseases has shown benefit to slow the
decline in renal function. In particular, the use of
angiotensin converting enzyme inhibitors (ACE-I)
and angiotensin receptor blockers (ARB) to block
the RAAS has shown additional benefits (55, 56).
Although many clinical trials have been undertaken
to halt the progression of renal failure by optimal
control of blood pressure and micro-albuminuria
with RAAS blockade, there has been no data to show
significant decrease in the inevitable progression to
renal failure (57, 58). However, there is a general
consensus that early identification of ADPKD individuals and achieving optimal blood pressure control
with ACE-I and other agents remain crucial in preventing the cardiovascular morbidity and mortality
associated with this disease (59).
Studies which included ambulatory blood pressure
monitoring have shown that in children and young
adults with ADPKD, increases in left ventricular
mass index occurred earlier than changes in renal
volume in the hypertensive and borderline hypertensive group (60). In addition, the most significant
finding was that even among the normotensive
children, higher indices were noted in those within
the upper quartile of the normal blood pressure. This
suggests that cardiovascular organs remain vulnerable targets in ADPKD patients, even in the early
stages of the disease.
Interestingly, the likelihood of hypertension in
ADPKD patients is significantly greater when the
affected parent was hypertensive (61). Thus, the
family history is especially critical in this case,
although it is not immediately understood whether
this association is related to genetic modifiers or
polymorphisms with regards to RAAS (62). One
caveat is that pharmacological agents prescribed to
inhibit RAAS result in incomplete inhibition of the
RAAS. Angiotensin II, for example, can be generated via multiple pathways (Figure 2). Consistent
with this view, the inhibition of RAAS activation by
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Figure 2. Hypertension in polycystic kidney disease
Renal cysts are thought to compress and disrupt the vascular network in the kidney. The kidney would then become ischemic,
which would induce renin release from the juxtaglomerular apparatus. The increase in renin secretion could accelerate the
conversion of angiotensinogen to angiotensin I, which is converted by angiotensin converting enzyme (ACE) to angiotension
II. Activation of angiotensin receptor (AT1) would initiate cascades of physiological responses that would lead to hypertension. Additional secondary pathways exist in converting angiotensinogen to angitotensin II. As indicated by the light arrows,
these secondary pathways involve chymase, tonin and/or cathepsin G.

ACE inhibitors has not been always proven to retard
the course of the disease, compared to results seen
in renal diseases with primary glomerular injury
(63). There are also other factors contributing to
the increase in blood pressure. Tubular dysfunction
caused by structural changes leading to retention
of sodium and water and increased sympathetic
activity, for example, is seen in ADPKD patients
(64). Nonetheless, inhibition of RAAS activation
might provide a logical way to reduce factors that
contribute to the propensity for high blood pressure
in ADPKD (Figure 2).
Vascular remodeling
There is growing evidence in literature that once
a change in GFR is observed, extensive vascular remodeling has already occurred (43-47). Scientists and
clinicians have been focusing their efforts on characterizing early biomarkers of injury. Increased urinary
excretion of MCP-1 (monocyte chemoattractant

protein-1) in adult patients with ADPKD has been
reported, and microalbuminuria has been established
as a frequent sign of progression of the disease (65,
66). Recently, changes in vascular remodeling with
altered intima-media thickness of carotid arteries
(CIMT), impaired endothelial-dependent vascular
relaxation (EDVR) and vascular ultrasound thickness have been reported in ADPKD patients (15, 45,
47, 67-70). CIMT in hypertensive ADPKD patients
and patients with essential hypertension was significantly greater than that of normotensive ADPKD
patients and healthy subjects. In addition, CIMP
in normotensive ADPKD patients is significantly
greater than in healthy subjects.
Polycystin-1 and polycystin-2 are expressed
in vascular smooth muscle cells (71, 72). These
proteins have an important role in maintaining the
integrity of dense plaques of the arterial wall (73).
Aortic root dilatation is a known finding in patients
with ADPKD, and aortic dissection is a known extra
International Journal of Nephrology & Urology, 2010; 2(2):294-308

298

Primary Cilia and Cardiovascular ADPKD

renal complication in these patients (7). Altered
expression of polycystins in arterial smooth muscle
cells, together with collagen disruption and cystic degeneration, has been seen in histological specimens
of aortic dissections and cerebral aneurysms from
patients with ADPKD. It has further been reported
that altered functional polycystins would result in
various degrees of cardiovascular abnormalities
(49-52). In addition to focal hemorrhage, altered
polycystin function in the mouse model exhibits
progressive total body edema, a feature of cardiac
failure (52).
An important question that remains unanswered
is whether or not changes in vasculature is a direct
result of the enlargement of the kidney. Nonetheless it is known that the remodeling of vasculature
is a counter beneficiary that can result in a more
severe hypertension (74-76). Vascular remodeling
in the arteries may develop through inward/outward
hypotrophic or hypertrophic mechanisms (77).
In either instance, vascular remodeling will place
greater stress on the cardiovascular system. In light
of this view, several anti-proliferative therapies have
been proposed as potential treatments in ADPKD.
At present, however, the immediate impact of this
therapy on blood pressure is still unknown.
Other contributing factors
Other factors that may contribute to cardiovascular hypertension in ADPKD include insulin resistance, asymmetric dimethylarginine (ADMA), and
vascular cilia dysfunction.
Numerous studies have shown a causal association between insulin resistance or hyperinsulinemia
and hypertension. Insulin resistance and concomitant hyperinsulinemia are present very early in the
course of renal diseases including in ADPKD (78,
79). Increased sympathetic activity present in individuals with chronic renal disease can contribute
to derangements of glucose metabolism (80). Although the mechanistic relationship between insulin
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resistance and polycystic kidney disease is not clear,
the correlation between insulin resistance and left
ventricular mass index in individuals with polycystic
kidney disease has been shown to be independent of
age, weight, systolic blood pressure and albuminuria
(79). Thus, ADPKD patients with insulin resistance
could have a more complex outcome on cardiovascular complications. Insulin-mediated sodium retention, increased sympathetic activity, impairment of
endothelial nitric oxide production and increased
endothelin-1 secretion have been suggested to worsen
vascular hypertension due to insulin resistance (81).
However, their relevance with regards to polycystic
kidney remains to be explored further.
To further examine endothelial function in
ADPKD, the plasma concentrations of vasodilator
nitric oxide were measured in twenty seven ADPKD
patients and twenty seven healthy controls. In this
study, the plasma concentration of nitric oxide was
shown to be reduced in ADPKD patients, confirming
an association between ADPKD and endothelial dysfunction (82). To further substantiate the endothelial
dysfunction in ADPKD, levels of ADMA (a marker
of an inhibitor of nitric oxide synthase) were significantly increased in patients with early ADPKD
compared to healthy age-matched individuals (83).
Although the significance of ADMA in ADPKD is
not immediately understood, endothelia-dependent
vasodilation offers substantial evidence which is too
important to ignore.
Cilia and their functions have been reported to
play essential roles in renal epithelial cells and in
cystic kidney diseases. Vascular cells, too, have cilia
(Figure 3). Endovascular cilia are thought to function
as local regulators of blood vessel (20, 25, 84-87).
Local regulation of blood vessels, also known as
autoregulation, is a necessary mechanism to achieve
immediate control of blood pressure within a region.
Autoregulation is an effective and efficient way to
control the amount of blood flow locally without
altering the neighboring systems significantly (88).
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Figure 3. Primary cilia and hypertension
Primary cilia are believed to play significant roles in the formation of renal cysts and the development of hypertension in
ADPKD. a. Within the lumen of a blood vessel, each vascular endothelial cell possesses one primary cilium, originated from
the apical cell membrane. Cilium is projected from “mother” centriole, which is also known as basal body. Similar to their
function in the renal tubule which is to sense urine flow, cilia in the endothelial lining of a vessel are hypothesized to sense
blood flow (shear stress). b. Projecting into the lumen, cilia function like antennae to sense changes in blood flow or pressure.
Femoral arteries from adult rodents were isolated and prepared for fluorescence imaging studies. A segment of the artery
was embedded in OCT solution, and sectioned at a thickness of 5 μm. The image was taken at 10x to outline the embedded
tissue. c. The embedded tissue was fixed and labeled with antibody against polaris, a structural protein for cilia. The presence of cilia was observed using florescence imaging. d, e. Arterial segments from femoral arteries of adult rodents were
cut open and coated with 10 μm of gold particles and analyzed with scanning electron microscopy. White arrows indicate
the presence of cilia. f. Upon sensing these changes, mechanosensory polycystins complex is activated. This results in
the influx of extracellular calcium that would initiate biochemical cascades that lead to production of NO vasodilator through
endothelial nitric oxide (eNOS). Activation of eNOS also depends on the contribution of calmodulin (CaM), phosphoinositide
kinase-3 (PI3K) Akt/protein kinase B (PKB) in addition to calcium-dependent protein kinase (PKC).

In the most recent studies within the cardiovascular field (20, 25), it is shown that each endothelial
cell has one primary cilium, and shear stress that
produces enough drag force on the cell surface
is able to bend and “activate” the primary cilium
(Figure 3). Although the biophysical properties of
vascular cilia are less studied and not well known,
it has been proposed that endothelial cilia are shear
stress sensors (20, 25). In addition, when non-

ciliated cells are challenged with fluid-shear stress,
they show significantly less induction of the shear
marker Krüppel-Like Factor-2, as compared to
ciliated endothelial cells (84, 86). Because primary
cilia sense only a low range of fluid-shear stress,
endothelial cells in vivo most likely project the cilia
in the areas with more subtle shear stress. Consistent with this idea, cilia in vascular endothelial cells
disassemble after a long exposure to high fluid shear

International Journal of Nephrology & Urology, 2010; 2(2):294-308
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stress (89). Because atherosclerosis also develops in
the arterial system at sites of low shear stress, cilia
have been further proposed to play an important role
in atherogenesis, a process of forming atheromas in
the inner lining of arteries (87).
As micro-sensory compartments, ciliary functions
depend on mechano-proteins such as polycystin-1
and polycystin-2 (Figure 3). Thus, the overall functions of these sensory compartments depend on both
functional and structural cilia proteins. Within a
blood vessel, an abrupt increase in blood pressure
or shear stress can be detected by these sensory
proteins localized in the cilia (20, 25). With cilia as
a local regulatory mechanism, the extracellular fluid
mechanics can then be transduced and translated into
a complex of intracellular signaling, which in turn
would activate eNOS - an endothelial enzyme that
synthesizes nitric oxide (NO) gas. The release of NO
from endothelial cells will diffuse to the neighboring
smooth muscle cells, thereby, promoting vasodilation
(90-92). The overall cilia dysfunction in ADPKD
may thus result in an increased total peripheral resistance, thereby increasing blood pressure.
Treatment of hypertension in ADPKD
Mutations in PKD1 and PKD2 have been suggested to contribute to vascular hypertension (30,
93, 94). This is probably due to failure to convert an
increase in mechanical blood flow into cellular NO
biosynthesis in order to control the vascular tone, i.e.
blood pressure (20, 25). Of note is that hypertension
occurs at a much earlier age in patients with ADPKD
than in the general population (95). The median age
of hypertension in ADPKD is about 30 years, compared with a median age of 45-55 years in patients
with essential hypertension (61). Hypertension occurs in children even before they are diagnosed with
ADPKD (96-99) or before any substantial reduction
in glomerular filtration rate is observed (100, 101).
Uncontrolled hypertension can, in fact, deteriorate kidney function much faster. In ADPKD,
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some studies have further suggested that high blood
pressure would promote faster cyst growth (102,
103). Early and effective treatments of hypertension
become very important to decrease the morbidity
and mortality of patients with ADPKD, including
the dreaded complication of intracranial aneurysm
ruptures (12, 97). Therefore, it makes sense to control the blood pressure in young ADPKD patients
aggressively.
Antihypertensives
Studies in experimental models of polycystic kidney disease have shown that the ACE-I enalapril or
the ARB losartan are more effective in lowering blood
pressure, maintaining renal volume and preserving
renal function than hydralazine (104). Moreover, in
a seven-year prospective study comparing rigorous
versus standard blood pressure control, enalapril
was found to be more effective than calcium channel blocker amlodipine in reducing left ventricular
mass index (LVMI). However, none of these agents
affects the rate of decline in renal function (105).
Similarly, an atenolol-based regimen, compared to
enalapril, showed no difference in decline of renal
function over a three-year period (106). In a six
months of follow-up study, ARB candesartan shows
little change in blood pressure or renal progression
in ADPKD patients (107). However, candesartan
reduced excretion of urinary fatty acid binding
protein, which has been reported to be higher in
ADPKD patients.
It was also reported that muscle sympathetic
nerve activity is increased in hypertensive patients
with ADPKD, regardless of renal function (64, 108).
This suggests that sympathetic hyperactivity could
contribute to the pathogenesis of hypertension in
ADPKD. However, it is not immediately understood
whether the sensitivity to sympathetic nerve activity
is a secondary effect due to an increase in RAAS
system (Figure 2). Of apparent complexity is that
angiotensin can stimulate the sympathetic nervous
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system and that sympathetic nerve activity can
also stimulate RAAS (109, 110). At least in murine
models of PKD, bilateral renal denervation could
reduce cystic kidney size, cyst volume and most
importantly, systolic blood pressure (111). It is
therefore very likely that sympathetic nerve activity
would activate RAAS system, which would increase
blood pressure.
Regardless, in a 3-year prospective randomized
double-blind study that compared ACE-I ramipril
and the beta-blocker metoprolol as first line therapy
in hypertensive ADPKD patients, no differences
in renal function or LVMI were detected (112).
However, LVMI increased in patients with standard
blood pressure control while it remained stable or
improved in patients with rigorous blood pressure
control, suggesting that aggressive blood pressure
control is necessary in ADPKD patients (113).
Aside from ACE-I, calcium channel blockers
have also been reported to reduce blood pressure
effectively and preserve renal function in ADPKD
patients (114). A different study, however, showed
that the renoprotective effect of ARB was considerably more favorable than calcium channel blocker in
the treatment of ADPKD (115). The use of diuretics
in hypertensive ADPKD patients also results in a
similar decrease in blood pressure, although they
may promote a faster loss of renal function compared
to ACE-I therapy (57). In addition, vasopressin V2
receptor antagonists have been proposed to have
anti-hypertensive effect (116), probably by reducing
renal sodium reabsorption.
Although a definitive study to demonstrate efficacy of ACE-I on renal progression in ADPKD is not
available, there is a wealth of evidence that suggest
ACE-I are beneficial in slowing renal progression in
non-diabetic kidney disease. Clinical practice guidelines from the National Kidney Foundation and the
Joint National Committee on Prevention Detection
Evaluation and Treatment of High Blood Pressure
call for ACE-I as the first line of agent for treatment of
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hypertension in patients with chronic kidney disease
(117-119). Although ACE-I and ARB are considered
first line agents to treat hypertension in ADPKD,
caution needs to be used in pregnant women due to
known birth defects and in advanced renal failure
due to risk of life-threatening hyperkalemia. Overall,
early and effective treatment of hypertension is very
important to decrease the morbidity and mortality of
patients with ADPKD.
Transplantation
Activation of the RAAS has been found in normotensive and hypertensive ADPKD subjects. As
cysts enlarge, they compress the renal vasculature
and attenuate the renal vessels, causing intrarenal
ischemia and activation of the RAAS (120-122).
Since cardiovascular abnormalities are thought to
initiate from the cystic kidneys in ADPKD, there has
been a great interest in studying the outcomes after
renal transplantation in these individuals. Earlier
outcome studies in renal transplant recipients with
ADPKD on azathiprine or cyclosporine immunosuppression have shown an increase in cardiovascular
morbidity compared to non-ADPKD transplant
recipients (123). However, cardiovascular events,
graft and patient survival up to 10 years of follow-up
were not found to be significantly different between
transplant recipients with ADPKD and non-diabetic
transplant recipients (124). The severity, rather than
occurrence, of urinary tract infections are more significant in post-transplant recipients with ADPKD
compared to their non-diabetic cohorts (124).
In a different report of eleven transplant cases
in hypertensive ADPKD, six patients showed improved blood pressure after transplantation (125).
Improved blood pressure was defined as the ability
to reduce antihypertensive drug treatment after renal
transplantation. These results suggest that while
renal transplantation seems to have some beneficial
outcomes, it is not sufficient to eradicate the hypertension in ADPKD patients. In an observational
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study on 312 children with ADPKD, it is further
reported that high blood pressure promotes a faster
renal volume growth (126). ADPKD children with
high blood pressure have faster renal growth than
those with lower blood pressure. This suggests that
hypertension is a risk factor independent from kidney
function in ADPKD. Hence, therapeutic interventions in controlling blood pressure remain necessary
and beneficial for ADPKD patients, regardless of
kidney function or transplant.
Novel therapy
Although ciliary therapy does not exist today, it is
appealing and tempting to speculate the possibility
of treatment for localized blood vessel injuries such
as aneurysm, atherosclerosis, dissection, edema,
hemorrhage, and vascular ectasia, among others
in ADPKD. In particular, endothelium-dependent
relaxation is impaired, and endothelial nitric oxide
synthase activity is decreased in patients with
ADPKD (63, 69, 127). The endothelial dysfunction
due to impaired release of NO in ADPKD patients
becomes a crucial pathogenesis of hypertension.
The imbalance in endothelium-derived vasoactive
mediators might therefore need to be considered
seriously in ADPKD patients (70, 128).
Of particular interest is a high level of polycystin expression in the vascular system, which is
required for the structural integrity of blood vessels
(72, 129-131). The expression of polycystins in
human endothelial cilia further provides a critical
link between cilia and the vasculature (20, 25, 89).
Although there are only limited reports on ciliary
polycystins in vascular endothelial cells, abnormal
expressions of polycystins are known to prevent
normal cilia function that converts changes in fluid
flow into biosynthesis of NO in interlobar arteries
obtained from ADPKD patients (20).
Interestingly, changes in extracellular fluid
flow can either activate or inactivate cilia function
through polycystin-1 and polycystin-2 complex (25).
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A sudden increase in blood flow, as seen in daily fluctuation of blood pressure, would activate cilia through
polycystin complex. This, in turn, would allow calcium
influx and initiate a series of biochemical cascades that
lead to NO production (Figure 3). NO is a very potent
physiological vasodilator that would decrease the
baseline tension (contraction) of the vessel, and thus
decrease vascular pressure. Subsequently, the dilation
of the vessel during a sudden increase in blood pressure
is a necessary local regulation to avoid focal injury of
the blood vessel.
On the other hand, prolonged exposure to higher blood
flow as seen in chronic hypertension would inactivate
cilia by down-regulating functional polycystin-1 (25).
Functional polycystin-1 as a mechanosensory molecule
can be inactivated by proteolytic cleavage after exposure to high fluid-shear stress. This may further suggest
that in patients with high blood pressure, cilia would
very unlikely sense minute changes in blood pressure,
which might result in failure to provide a mechanism to
autoregulate the local circulatory system. In addition,
the presence of cilia in vascular smooth muscle cells
has also been reported, and sensory polycystin-1 and
polycystin-2 complex is localized in the cilia (132). Although their roles are not clear at present, the vascular
cilia are positioned in such a way that they maintain
a specific alignment with respect to the lumen of the
artery. Further studies of the role of this alignment may
be necessary to shed light on their possible functions
with regard to vascular hypertension.
Current clinical trial in hypertensive ADPKD
There is a wealth of evidence to indicate that aggressive blood pressure control in ADPKD patients
is a clinical necessity, regardless of kidney function.
Drugs that inhibit the RAAS might be beneficial in
this context. However, more robust clinical studies
are essential to improve clinical outcomes with
greater certainty. In particular, we need a more
comprehensive clinical study to provide a greater
number of subjects, longer follow-up time with
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clear primary endpoints, and assessment of PKD1
or PKD2 mutation either through sequence analysis
or radiological imaging studies (133). An example
of such a comprehensive study that is currently
underway is HALT Progression of Polycystic Kidney Disease (HALT PKD), which is a clinical trial
evaluating the effectiveness of inhibiting RAAS in
blood pressure control. The study will also determine whether a combined therapy of an ACE-I and
an ARB would be superior than monotherapy ACE-I
alone to delay the progression of renal disease and
whether a more “rigorous” blood pressure (<110/75)
would be more effective than standard blood pressure target (<130/80) in preserving renal function
(5). There is certainly much work remaining, and
we are on the verge of conjuring and applying our
concept and understanding of ADPKD for a better
clinical practice and patient outcomes.
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